Published in Viral Immunol on January 01, 2006
One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther (2007) 1.36
Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience (2008) 1.30
Extended transgene expression from a nonintegrating adenoviral vector containing retroviral elements. Mol Ther (2008) 1.10
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol (2007) 0.99
CCL2-expressing astrocytes mediate the extravasation of T lymphocytes in the brain. Evidence from patients with glioma and experimental models in vivo. PLoS One (2012) 0.93
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A (1994) 8.13
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 5.27
MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity (1994) 4.65
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 4.02
Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med (1992) 3.52
Cognition and immunity; antibody impairs memory. Immunity (2004) 3.40
B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol (2001) 2.99
Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol (2004) 2.12
Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol (2002) 2.10
Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A (2000) 2.05
A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther (2002) 1.96
Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today (1992) 1.96
Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol (1995) 1.75
Immune responses to RNA-virus infections of the CNS. Nat Rev Immunol (2003) 1.74
Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells. J Virol (1990) 1.70
Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest (2004) 1.59
Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther (2001) 1.55
Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther (1998) 1.51
Adenovirus gene transfer causes inflammation in the brain. Neuroscience (1995) 1.50
In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med (2001) 1.46
Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum Gene Ther (2001) 1.41
Impaired T cell immunity in B cell-deficient mice following viral central nervous system infection. J Immunol (2001) 1.31
A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. J Neuroimmunol (1998) 1.31
Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Gene Ther (1994) 1.29
Perforin and gamma interferon-mediated control of coronavirus central nervous system infection by CD8 T cells in the absence of CD4 T cells. J Virol (2004) 1.24
The immunogenicity of intracerebral virus infection depends on anatomical site. J Virol (1997) 1.19
Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods (1996) 1.19
Mouse cell surface antigens: nomenclature and immunophenotyping. J Immunol (1998) 1.15
Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci (1996) 1.12
Immune responses to adenovirus vectors in the nervous system. Trends Neurosci (1996) 1.10
Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol (1998) 1.05
Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1+CD8 alpha+beta- TCR-alpha beta B220+ lymphokine-activated killer subset. J Immunol (1993) 1.03
A subfraction of B220(+) cells in murine bone marrow and spleen does not belong to the B cell lineage but has dendritic cell characteristics. Eur J Immunol (2002) 1.03
Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease. Gene Ther (2004) 0.99
Virus dissemination through the brain parenchyma without immunologic control. J Immunol (1997) 0.94
Progress and challenges in viral vector-mediated gene transfer to the brain. Curr Opin Mol Ther (2002) 0.92
Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects. Mol Ther (2004) 0.87
Role of B cell antigen processing and presentation in the humoral immune response. FASEB J (1991) 0.85
Adenoviruses encoding HPRT correct biochemical abnormalities of HPRT-deficient cells and allow their survival in negative selection medium. Metab Brain Dis (1999) 0.81
Humoral immune responses to adenovirus vectors in the brain. J Neuroimmunol (2000) 0.81
Uncoupling of virus-induced inflammation and anti-viral immunity in the brain parenchyma. J Gen Virol (2002) 0.81
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst (2002) 2.42
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 2.19
Loss of function of OsDCL1 affects microRNA accumulation and causes developmental defects in rice. Plant Physiol (2005) 1.77
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74
Brain edema after intracerebral hemorrhage in rats: the role of inflammation. Neurol India (2006) 1.69
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther (2007) 1.55
The relationship of hamstrings and quadriceps strength to anterior cruciate ligament injury in female athletes. Clin J Sport Med (2009) 1.55
In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med (2006) 1.52
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Hysteroscopic surgery of ectopic pregnancy in the cesarean section scar. J Minim Invasive Gynecol (2009) 1.46
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45
Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42
Roles of DCL4 and DCL3b in rice phased small RNA biogenesis. Plant J (2011) 1.42
Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol (2006) 1.41
ARGONAUTE10 and ARGONAUTE1 regulate the termination of floral stem cells through two microRNAs in Arabidopsis. PLoS Genet (2011) 1.40
SDG714, a histone H3K9 methyltransferase, is involved in Tos17 DNA methylation and transposition in rice. Plant Cell (2007) 1.39
Arginine methylation mediated by the Arabidopsis homolog of PRMT5 is essential for proper pre-mRNA splicing. Proc Natl Acad Sci U S A (2010) 1.36
One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther (2007) 1.36
Comparative analysis of JmjC domain-containing proteins reveals the potential histone demethylases in Arabidopsis and rice. J Integr Plant Biol (2008) 1.35
Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther (2009) 1.33
Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol (2006) 1.32
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol (2007) 1.31
Oryza sativa dicer-like4 reveals a key role for small interfering RNA silencing in plant development. Plant Cell (2007) 1.30
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A (2010) 1.29
Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res (2009) 1.24
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res (2009) 1.22
Mutations in the Type II protein arginine methyltransferase AtPRMT5 result in pleiotropic developmental defects in Arabidopsis. Plant Physiol (2007) 1.22
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
AGAMOUS terminates floral stem cell maintenance in Arabidopsis by directly repressing WUSCHEL through recruitment of Polycomb Group proteins. Plant Cell (2011) 1.22
Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res (2006) 1.22
Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther (2005) 1.20
JMJ14 is an H3K4 demethylase regulating flowering time in Arabidopsis. Cell Res (2010) 1.17
Human rhinovirus C infections mirror those of human rhinovirus A in children with community-acquired pneumonia. J Clin Virol (2010) 1.16
Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther (2004) 1.14
The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. Menopause (2009) 1.13
ABI4 regulates primary seed dormancy by regulating the biogenesis of abscisic acid and gibberellins in arabidopsis. PLoS Genet (2013) 1.13
Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther (2006) 1.12
WU and KI polyomavirus present in the respiratory tract of children, but not in immunocompetent adults. J Clin Virol (2008) 1.12
The epidemiology and burden of rotavirus in China: a review of the literature from 1983 to 2005. Vaccine (2006) 1.11
In vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells. J Immunol (2008) 1.09
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09
Epidemiological study of urge urinary incontinence and risk factors in China. Int Urogynecol J (2010) 1.09
ROR1/RPA2A, a putative replication protein A2, functions in epigenetic gene silencing and in regulation of meristem development in Arabidopsis. Plant Cell (2005) 1.09
Adenovector GAD65 gene delivery into the rat trigeminal ganglion produces orofacial analgesia. Mol Pain (2009) 1.07
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther (2011) 1.07
Human rhinovirus group C infection in children with lower respiratory tract infection. Emerg Infect Dis (2008) 1.06
Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci (2010) 1.05
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther (2008) 1.05
Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther (2008) 1.05